Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

References for PMC Articles for PubMed (Select 21633595)

1.

Epidemiology of hepatitis B and C viruses: a global overview.

Te HS, Jensen DM.

Clin Liver Dis. 2010 Feb;14(1):1-21, vii. doi: 10.1016/j.cld.2009.11.009. Review.

PMID:
20123436
2.

Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production.

Gharagozloo M, Velardi E, Bruscoli S, Agostini M, Di Sante M, Donato V, Amirghofran Z, Riccardi C.

Pharmacol Res. 2010 May;61(5):405-9. doi: 10.1016/j.phrs.2009.12.017. Epub 2010 Jan 7.

PMID:
20056147
3.

Antioxidant and antiviral activities of silybin fatty acid conjugates.

Gazák R, Purchartová K, Marhol P, Zivná L, Sedmera P, Valentová K, Kato N, Matsumura H, Kaihatsu K, Kren V.

Eur J Med Chem. 2010 Mar;45(3):1059-67. doi: 10.1016/j.ejmech.2009.11.056. Epub 2009 Dec 6.

PMID:
20036447
4.

Evaluation of the genotoxic and anti-genotoxic activities of silybin in human hepatoma cells (HepG2).

Angeli JP, Barcelos GR, Serpeloni JM, Barbosa F Jr, Nersesyan A, Mantovani MS.

Mutagenesis. 2010 May;25(3):223-9. doi: 10.1093/mutage/gep064. Epub 2009 Dec 23.

5.

A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis.

Serviddio G, Bellanti F, Giudetti AM, Gnoni GV, Petrella A, Tamborra R, Romano AD, Rollo T, Vendemiale G, Altomare E.

J Pharmacol Exp Ther. 2010 Mar;332(3):922-32. doi: 10.1124/jpet.109.161612. Epub 2009 Dec 11.

6.

Preparation and characterization of silybin-loaded nanostructured lipid carriers.

Jia LJ, Zhang DR, Li ZY, Feng FF, Wang YC, Dai WT, Duan CX, Zhang Q.

Drug Deliv. 2010 Jan;17(1):11-8. doi: 10.3109/10717540903431586. Epub 2009 Nov 26.

PMID:
19941406
7.

Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.

Brantley SJ, Oberlies NH, Kroll DJ, Paine MF.

J Pharmacol Exp Ther. 2010 Mar;332(3):1081-7. doi: 10.1124/jpet.109.161927. Epub 2009 Nov 24.

8.

Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.

Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Berman J, Liu QY, Doo E, Fried MW; SyNCH Trial Group.

J Clin Pharmacol. 2010 Apr;50(4):434-49. doi: 10.1177/0091270009347475. Epub 2009 Oct 19.

10.

Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection.

Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, Sloan DD, Graf TN, Oberlies NH, Lee DY, Jerome KR, Polyak SJ.

Gastroenterology. 2010 Feb;138(2):671-81, 681.e1-2. doi: 10.1053/j.gastro.2009.09.021. Epub 2009 Sep 24.

11.

Herb-drug interaction of silymarin or silibinin on the pharmacokinetics of trazodone in rats.

Chang JC, Wu YT, Lee WC, Lin LC, Tsai TH.

Chem Biol Interact. 2009 Dec 10;182(2-3):227-32. doi: 10.1016/j.cbi.2009.09.005. Epub 2009 Sep 16.

PMID:
19765569
12.
13.

Free radical scavenging reactions and antioxidant activities of silybin: mechanistic aspects and pulse radiolytic studies.

Fu H, Lin M, Muroya Y, Hata K, Katsumura Y, Yokoya A, Shikazono N, Hatano Y.

Free Radic Res. 2009 Sep;43(9):887-97. doi: 10.1080/10715760903136996.

PMID:
19685362
14.

Silibinin modulates biotransforming microbial enzymes and prevents 1,2-dimethylhydrazine-induced preneoplastic changes in experimental colon cancer.

Sangeetha N, Felix AJ, Nalini N.

Eur J Cancer Prev. 2009 Sep;18(5):385-94. doi: 10.1097/CEJ.0b013e32832d1b4f.

PMID:
19654488
15.

Silibinin attenuates amyloid beta(25-35) peptide-induced memory impairments: implication of inducible nitric-oxide synthase and tumor necrosis factor-alpha in mice.

Lu P, Mamiya T, Lu LL, Mouri A, Niwa M, Hiramatsu M, Zou LB, Nagai T, Ikejima T, Nabeshima T.

J Pharmacol Exp Ther. 2009 Oct;331(1):319-26. doi: 10.1124/jpet.109.155069. Epub 2009 Jul 28.

16.

A comparative study on the stability of silybin and that in silymarin in buffers and biological fluids.

Tang N, Wu D, Lu Y, Chen J, Zhang B, Wu W.

Drug Metab Lett. 2009 Apr;3(2):115-9.

PMID:
19601873
17.

Silibinin inhibits translation initiation: implications for anticancer therapy.

Lin CJ, Sukarieh R, Pelletier J.

Mol Cancer Ther. 2009 Jun;8(6):1606-12. doi: 10.1158/1535-7163.MCT-08-1152. Epub 2009 Jun 9.

18.

Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.

Biermer M, Berg T.

Gastroenterology. 2009 Jul;137(1):390-1. doi: 10.1053/j.gastro.2009.02.087. Epub 2009 May 30. No abstract available.

PMID:
19486953
19.

Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells.

Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, di Manzano C, Marra F, Loguercio C, Pinzani M.

J Hepatol. 2009 Jun;50(6):1102-11. doi: 10.1016/j.jhep.2009.02.023. Epub 2009 Apr 5.

PMID:
19398228
20.

Differential effects of silymarin and its active component silibinin on plasma membrane stability and hepatocellular lysis.

Basiglio CL, Sánchez Pozzi EJ, Mottino AD, Roma MG.

Chem Biol Interact. 2009 May 15;179(2-3):297-303. doi: 10.1016/j.cbi.2008.12.008. Epub 2008 Dec 24.

PMID:
19135039
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk